Janel World Trade Ltd. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended September 30, 2013
January 14, 2014 at 04:01 pm
Share
Janel World Trade Ltd. reported unaudited consolidated earnings results for the fourth quarter and year ended September 30, 2013. For the quarter, the company reported revenue of $12,841,886, income from continuing operations of $63,267, income from continuing operations before income taxes of $28,612, net income from continuing operations of $22,612 and net loss available to common shareholders of $1,451,006 or $0.06 per diluted share against revenue of $14,447,610, income from continuing operations of $63,046, income from continuing operations before income taxes of $35,102, net loss from continuing operations of $1,750,817 and net loss available to common shareholders of $1,822,611 or $0.08 per diluted share for the same period a year ago.
For the year, the company reported revenue of $44,744,518, loss from continuing operations of $188,369, loss from continuing operations before income taxes of $314,106, net loss from continuing operations of $331,106 or $0.01 per diluted share and net loss available to common shareholders of $2,173,234 or $0.09 per diluted share against revenue of $49,837,461, income from continuing operations of $30,425, loss from continuing operations before income taxes of $65,029, net loss from continuing operations of $1,286,333 or $0.06 per diluted share and net loss available to common shareholders of $2,693,716 or $0.12 per diluted share for the same period a year ago.
Janel Corporation is a holding company. The Company operates through three segments: Logistics, Life Sciences and Manufacturing. The Company's Logistics segment consists of various wholly owned subsidiaries. Its Logistics segment is a non-asset based, full- service provider of cargo transportation logistics management services, including freight forwarding via air, ocean and land-based carriers, customs brokerage services, warehousing and distribution services, trucking, and other logistics services. The Life Sciences segment manufactures and distributes monoclonal and polyclonal antibodies, diagnostic reagents and other immunoreagents for biomedical research and provides antibody manufacturing for academic and industry research scientists. The Manufacturing segment consists of Indco, Inc. (Indco), subsidiary of the Company, which manufactures and distributes mixing equipment and apparatus for specific applications within various industries. Indco serves small- to mid-sized businesses.